HC Wainwright restated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research report sent to investors on Monday, Stock Target Advisor reports. They currently have a $40.00 price target on the stock.
Other research analysts also recently issued reports about the company. Canaccord Genuity lifted their target price on Y-mAbs Therapeutics from $35.00 to $40.00 and gave the stock a buy rating in a research note on Monday, October 28th. Wedbush started coverage on Y-mAbs Therapeutics in a research note on Tuesday, September 3rd. They set an outperform rating and a $38.00 target price for the company. ValuEngine upgraded Y-mAbs Therapeutics from a sell rating to a hold rating in a research note on Friday, November 1st. Cowen reiterated a buy rating on shares of Y-mAbs Therapeutics in a research note on Monday, October 28th. Finally, Zacks Investment Research upgraded Y-mAbs Therapeutics from a hold rating to a buy rating and set a $34.00 price target for the company in a research note on Saturday, November 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $38.00.
Shares of NASDAQ YMAB traded up $0.03 during midday trading on Monday, hitting $28.54. 308,779 shares of the company’s stock were exchanged, compared to its average volume of 143,032. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.02. Y-mAbs Therapeutics has a 12 month low of $15.17 and a 12 month high of $32.90. The company’s 50 day moving average price is $27.79 and its 200 day moving average price is $24.92. The firm has a market capitalization of $1.13 billion, a PE ratio of -19.02 and a beta of 1.19.
Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Wednesday, November 13th. The company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.16). On average, equities research analysts anticipate that Y-mAbs Therapeutics will post -2.23 EPS for the current year.
In related news, Chairman Thomas Gad sold 4,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $25.77, for a total value of $103,080.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Johan Wedell-Wedellsborg sold 168,244 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $27.57, for a total value of $4,638,487.08. The disclosure for this sale can be found here. Insiders sold a total of 351,260 shares of company stock valued at $9,504,735 over the last 90 days. 38.40% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of Montreal Can acquired a new position in Y-mAbs Therapeutics in the 2nd quarter valued at $39,000. California Public Employees Retirement System acquired a new position in Y-mAbs Therapeutics in the 3rd quarter valued at $254,000. Swiss National Bank acquired a new position in Y-mAbs Therapeutics in the 2nd quarter valued at $290,000. Tuttle Tactical Management acquired a new position in Y-mAbs Therapeutics in the 3rd quarter valued at $309,000. Finally, Wells Fargo & Company MN raised its holdings in Y-mAbs Therapeutics by 422.2% in the 2nd quarter. Wells Fargo & Company MN now owns 19,203 shares of the company’s stock valued at $438,000 after acquiring an additional 15,526 shares in the last quarter. 32.58% of the stock is owned by hedge funds and other institutional investors.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Recommended Story: Trading based on a resistance level
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.